

Table 2 Antigens of human leukocyte antigen (HLA) class I and II regions showing significant difference between inflammatory bowel disease patients and controls

HLA antigens	Inflammatory bowel disease (n = 65)		Controls (n = 67)		Odds ratio	EF or PF	P-value ^a	95% CI
	No.	%	No.	%				
A9	34	52.3	12	17.9	4.72	0.40	< 0.001	2.02–11.36
A11	2	3.1	15	22.4	0.11	0	^b	0.01–0.51
A30	4	6.2	14	20.9	0.25	0		0.06–0.86
A33	3	4.6	11	16.4	0.25	0.12	0	0.04–1.01
B41	43	66.2	4	6.0	30.78	0.64	< 0.001	9.35–127.42
B51	11	16.9	25	37.3	0.34	0		0.14–0.83
DR4	22	33.8	9	13.4	3.30	0		1.29–8.91
DR5	11	16.9	2	3.0	6.62	0		1.34–63.23
DR7	5	7.7	16	23.9	0.27	0		0.07–0.83
DR8	20	30.8	6	9.0	4.52	0.		1.57–14.73
DQ2	16	24.6	7	10.4	2.80	0		0.99–8.65

^aFisher exact test.

^bCorrected P-value significant.

n = total number of patients; EF = etiological fraction, PF = preventive fraction, CI = confidence interval.